SU1342500A1 - Method of treatment of glaucoma - Google Patents
Method of treatment of glaucoma Download PDFInfo
- Publication number
- SU1342500A1 SU1342500A1 SU823404836A SU3404836A SU1342500A1 SU 1342500 A1 SU1342500 A1 SU 1342500A1 SU 823404836 A SU823404836 A SU 823404836A SU 3404836 A SU3404836 A SU 3404836A SU 1342500 A1 SU1342500 A1 SU 1342500A1
- Authority
- SU
- USSR - Soviet Union
- Prior art keywords
- ring
- eye
- papain
- electrophoresis
- drainage
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 6
- 208000010412 Glaucoma Diseases 0.000 title claims description 5
- 229920001817 Agar Polymers 0.000 claims abstract description 7
- 108090000526 Papain Proteins 0.000 claims abstract description 7
- 239000004365 Protease Substances 0.000 claims abstract description 7
- 239000008272 agar Substances 0.000 claims abstract description 7
- 229940055729 papain Drugs 0.000 claims abstract description 7
- 235000019834 papain Nutrition 0.000 claims abstract description 7
- 208000014674 injury Diseases 0.000 claims abstract description 3
- 230000008733 trauma Effects 0.000 claims abstract description 3
- 238000001962 electrophoresis Methods 0.000 claims description 8
- 239000003792 electrolyte Substances 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 description 3
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 2
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 2
- 230000003547 miosis Effects 0.000 description 2
- 239000003604 miotic agent Substances 0.000 description 2
- 229960001416 pilocarpine Drugs 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- OGDVEMNWJVYAJL-LEPYJNQMSA-N Ethyl morphine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OCC OGDVEMNWJVYAJL-LEPYJNQMSA-N 0.000 description 1
- 241001442654 Percnon planissimum Species 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 210000004240 ciliary body Anatomy 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/007—Methods or devices for eye surgery
- A61F9/00781—Apparatus for modifying intraocular pressure, e.g. for glaucoma treatment
Landscapes
- Health & Medical Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Surgery (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Vascular Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Изобретение относитс к офтальмологии . Цель изобретени - упрощение способа и уменьшение травматич- ности. Агаровое кольцо укладывают в проекции дренажной системы, сверху подвод т кольцевой активный электрод. Сила тока при введении папаина 0,2- 0,4 мА. Толщину активного электрода подбирают таким образом, чтобы плотность тока бьша не более 0,057 мА/мм Положение дренажной зоны определ ют с помощью диафаноскопа.This invention relates to ophthalmology. The purpose of the invention is to simplify the method and reduce the trauma. The agar ring is placed in the projection of the drainage system, and an annular active electrode is supplied from above. The current strength with the introduction of papain 0,2-0,4 mA. The thickness of the active electrode is selected so that the current density is no more than 0.057 mA / mm. The position of the drainage zone is determined with the help of a diaphanoscope.
Description
Изобретение относитс к медицине, в частности к офтальмологии.This invention relates to medicine, in particular to ophthalmology.
Цель изобретени - упрощение способа и уменьшение его травматичности благодар тому, что лекарственные вещества ввод т в область дренажной зоны путем электрофореза из кольцевых агаровых слепков, диаметр которых соответствует диаметру дренажной зоны, соответствующего диаметра выбиThe purpose of the invention is to simplify the method and reduce its trauma due to the fact that medicinal substances are introduced into the drainage zone by electrophoresis of annular agar casts, the diameter of which corresponds to the diameter of the drainage zone corresponding to the diameter
раетс и активный кольцевой электродactive and active electrode electrode
Способ осуществл ют следующим образом .The method is carried out as follows.
После эпибульбарной инстилл цион- ной анестезии 0,25%-ным дикаином на ILUIT с микрометрической линейкой при подсветке диафаноскопом через пара- оптическую зону роговицы определ ют положение дренажной зоны в линейных единицах. Провод т подсветку, определ ют переднюю границу цилиарного тела, котора выгл дит черным кольцом Hk фоне розового свечени лимба. Резкость изображени наводитс на переднюю поверхность хрусталика. Измер ют горизонтальный диаметр черного кольца в миллиметрах, что и соответствует (в сопоставлении с гониоск пическими данными) положению дренаж- ной зоны. Полученный диаметр в миллиметрах служит критерием дл выбора диаметра активного кольцевого электрода и кольцевого агарового слепка. В жидкий остывающий агар внос т папа ин из расчета 0,02% или дионин из расчета 2% и разливают в специальные формы. Полученный кольцевидный слепо 5%-ного агара имеет высоту и ширину по 2 мм, скошенность внутренней поверхности 30°, что соответствует кривизне глазного блока в области лимба. Агаровое кольцо укладывают в проекции дренажной системы, сверху подвод т кольцевлй активный электрод Сила тока при введении папаина 0,2- 0,4 мА. Врем сеанса при введении папаина 4 мин. Толщину активного электрода подбирают таким образом, чтобы плотность тока бьша не болееAfter epibulbar instillation anesthesia with 0.25% dikain on ILUIT with a micrometric scale, when illuminated with a diaphanoscope through the para-optical zone of the cornea, the position of the drainage zone is determined in linear units. Illumination is conducted, the front border of the ciliary body is determined, which is seen by the black ring Hk against the background of the pink glow of the limbus. The sharpness of the image is brought to the front surface of the lens. The horizontal diameter of the black ring in millimeters is measured, which corresponds (in comparison with the gonioscopic data) to the position of the drainage zone. The resulting diameter in millimeters serves as a criterion for selecting the diameter of the active ring electrode and the ring agar impression. Papa in is introduced into the liquid cooling agar at the rate of 0.02% or dionin at the rate of 2% and poured into special forms. The resulting annular blindly 5% agar has a height and width of 2 mm, the skewness of the inner surface 30 °, which corresponds to the curvature of the eye block in the limbus. The agar ring is placed in the projection of the drainage system, an annular active electrode is supplied from above. The current strength when introducing papain is 0.2-0.4 mA. Session time with the introduction of papain 4 min. The thickness of the active electrode is chosen so that the current density is no more than
22
0,057 мА/мм , так как больша плотность тока вызывает ожог коньюктивы.0.057 mA / mm since a high current density causes a conjunctival burn.
Пример. Больной С., 58 лет поступил по поводу открытоугольной начальной с умеренно повышенным ВГД с максимальным режимом миотиков глаукомы левого глаза. До операции:Example. Patient S., 58 years old, was admitted about the open primary with moderately elevated IOP with the maximal miotics regime for glaucoma of the left eye. Before surgery:
27,76, ,12, ,09, .27.76,, 12,, 09,.
00
00
Q Q
Оперативное лечение не проводилось. После трех сеансов локального электрофореза папаина в область дренажной системы глаза при силе тока 0,2 мА и продолжительности сеанса 2 мин наступила компенсаци отфталь- мотонуса - Р, 15,88,. ,21 , ,23, .Surgical treatment was not carried out. After three sessions of local electrophoresis of papain, in the area of the eye drainage system with a current of 0.2 mA and a session duration of 2 minutes, the otfatomotonus was compensated - P, 15.88 ,. , 21, 23,.
П р и м е р 2. Больной М., 68 лет поступил по поводу открытоугольной развитой с высоким ВГД п/м глаукомы левого глаза.PRI mme R 2. Patient M., 68 years old, was enrolled for an open-angle developed IOP with high IOP in glaucoma of the left eye.
Провод т 5 сеансов локального 5 электрофореза папаина на область дренажной системы глаза при силе тока 0,4 мА, продолжительность сеанса 4 мин. Оперативное лечение отложено вследствие полной компенсации офталь- мотонуса при двухкратном закапывании пилокарпина.Conducted 5 sessions of local 5 electrophoresis of papain in the area of the eye drainage system with a current of 0.4 mA, the duration of the session 4 min. Surgical treatment was postponed due to the complete compensation of the ophthalmic motility with double instillation of pilocarpine.
До лечени : ,4, ,08, коэффициент Беккера (КБ)417.Before treatment:, 4,, 08, Becker's coefficient (CB) 417.
После электрофореза: Р(25,47, 25 ,16, .After electrophoresis: P (25.47, 25, 16,.
После электрофореза и двухкратных инстилл ций пилокарпина: ,3| ,19, .After electrophoresis and double instillation of pilocarpine:, 3 | ,nineteen, .
П р и м е р 3. Больной У., 62 года . Диагноз: открытоугольна начальна с высоким ВГД при максимальном режиме миотиков глаукома правого глаза .PRI me R 3. Patient U., 62 years. Diagnosis: open-angle, early with high IOP, with maximal miotics, glaucoma of the right eye.
Провод т 3 сеанса локального электрофореза папаина на область дренажной системы из гелевых слепков при силе тока 0,3 мА в течение 3 мин.3 sessions of local electrophoresis of papain were conducted on the area of the drainage system from gel impressions with a current of 0.3 mA for 3 minutes.
До лечени : ,11, ,13, .Before treatment:, 11,, 13,.
После электрофореза: ,70, ,22,- .After electrophoresis:, 70,, 22, -.
Q Q
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SU823404836A SU1342500A1 (en) | 1982-03-09 | 1982-03-09 | Method of treatment of glaucoma |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SU823404836A SU1342500A1 (en) | 1982-03-09 | 1982-03-09 | Method of treatment of glaucoma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SU1342500A1 true SU1342500A1 (en) | 1987-10-07 |
Family
ID=21000249
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SU823404836A SU1342500A1 (en) | 1982-03-09 | 1982-03-09 | Method of treatment of glaucoma |
Country Status (1)
| Country | Link |
|---|---|
| SU (1) | SU1342500A1 (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7252655B2 (en) | 1999-05-25 | 2007-08-07 | Iomed, Inc. | Ocular iontophoretic apparatus handle |
| US7937142B2 (en) | 2004-04-30 | 2011-05-03 | Eyegate Pharma S.A.S. | Irritation-reducing ocular iontophoresis device |
| US8099162B2 (en) | 2005-11-29 | 2012-01-17 | Eyegate Pharma, S.A.S. | Ocular iontophoresis device |
| US9180292B2 (en) | 2008-12-31 | 2015-11-10 | Eyegate Pharmaceuticals, Inc. | System and method for ocular iontophoresis with buffering |
-
1982
- 1982-03-09 SU SU823404836A patent/SU1342500A1/en active
Non-Patent Citations (1)
| Title |
|---|
| Авторское свидетельство СССР № 799746, кл. А 61 F 9/00, 1981. * |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7252655B2 (en) | 1999-05-25 | 2007-08-07 | Iomed, Inc. | Ocular iontophoretic apparatus handle |
| US7937142B2 (en) | 2004-04-30 | 2011-05-03 | Eyegate Pharma S.A.S. | Irritation-reducing ocular iontophoresis device |
| US8306613B2 (en) | 2004-04-30 | 2012-11-06 | Eyegate Pharma S.A.S. | Irritation-reducing ocular iontophoresis device |
| US8611994B2 (en) | 2004-04-30 | 2013-12-17 | Eyegate Pharma S.A.S. | Irritation-reducing ocular iontophoresis device |
| US8099162B2 (en) | 2005-11-29 | 2012-01-17 | Eyegate Pharma, S.A.S. | Ocular iontophoresis device |
| US9238131B2 (en) | 2005-11-29 | 2016-01-19 | Eyegate Pharma S.A.S. | Ocular iontophoresis device |
| US9180292B2 (en) | 2008-12-31 | 2015-11-10 | Eyegate Pharmaceuticals, Inc. | System and method for ocular iontophoresis with buffering |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ritch | Plateau iris is caused by abnormally positioned ciliary processes | |
| Blok et al. | Use of the megasoft bandage lens for treatment of complications after trabeculectomy | |
| KR100514277B1 (en) | Ophthalmic Compositions of Neurotrophic Factors, Remedies for Optic Nerve Function Disorders and Method for Treating Optic Nerve Function Disorders | |
| Nakamura et al. | Ultrastructure of the vitreoretinal interface following the removal of the internal limiting membrane using indocyanine green | |
| ATE289815T1 (en) | USE OF SUBSTITUTED ISOQUINOLINE SULFONYL COMPOUNDS FOR PREPARING A MEDICATION FOR THE TREATMENT OF GLAUCOMA AND OCCULAR ISCHEMIA | |
| Cantor et al. | Glaucoma in the Maroteaux-Lamy syndrome | |
| CHANDLER et al. | Angle-closure glaucoma: subacute types | |
| Walland et al. | The effect of recurrent pterygium on corneal topography | |
| SU1342500A1 (en) | Method of treatment of glaucoma | |
| Hollands et al. | The effect of intracameral carbachol on intraocular pressure after cataract extraction | |
| Colucciello et al. | Macular hole following ruptured retinal arterial macroaneurysm | |
| Miller | Stellate ganglion block in glaucoma | |
| Brown et al. | Effect of cataract surgery on intraocular pressure reduction obtained with laser trabeculoplasty | |
| George et al. | Risk of dry eye after mullerectomy via the posterior conjunctival approach for thyroid-related upper eyelid retraction | |
| Funk et al. | Intraocular microendoscopy of the ciliary-process vasculature in albino rabbits: effects of vasoactive agents | |
| US5034406A (en) | Method for reducing or maintaining intraocular pressure | |
| Feller et al. | Breakdown and reestablishment of blood-aqueous barrier with laser trabeculoplasty | |
| Koster et al. | Acute angle-closure glaucoma in a patient with acquired immunodeficiency syndrome successfully treated with argon laser peripheral iridoplasty | |
| Koss et al. | Acute intraocular pressure elevation produced by argon laser trabeculoplasty in the cynomolgus monkey | |
| Stern et al. | Fluid-gas exchange after vitrectomy | |
| Lee et al. | Partial ciliary process laser photocoagulation in the management of glaucoma | |
| KR930019214A (en) | Ophthalmic Argatroban Formulations | |
| Hall | Prothesis treatment and its healing effect on central perforations of the tympanic membrane | |
| TYNER et al. | Mechanism of the miotic-resistant pupil with increased intraocular pressure | |
| SU1421337A1 (en) | Method of treatment of herpetic keratitis |